Walleye Trading’s Outlook Therapeutics OTLK Stock Holding History

Walleye Trading’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-754	Closed	-$33K	–	5716
2021 Q3	$33K	Buy	+754	New	+$36.4K	﹤0.01%	4752

Other funds holding OTLK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Walleye Trading's OTLK Position: Q4 2021 in Review

Walleye Trading sold out of Outlook Therapeutics (OTLK) in Q4 2021, closing a stake of 754 shares — an estimated $33K sold.

Walleye Trading first reported a position in OTLK in Q3 2021 and held it in 1 quarter. The position peaked at $33K in Q3 2021. 70 funds tracked by Wall St. Rank hold OTLK as of Q4 2021.

Walleye Trading reported no remaining Outlook Therapeutics position as of Q4 2021 after selling out during the quarter.
Walleye Trading sold 754 Outlook Therapeutics shares in Q4 2021, an estimated $33K.
Walleye Trading first reported a position in Outlook Therapeutics in Q3 2021 and held it in 1 quarter.
Walleye Trading's Outlook Therapeutics position peaked at $33K in Q3 2021.
70 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q4 2021.

Based on Walleye Trading's 13F filing for Q4 2021, filed 14 Feb 2022.